Literature DB >> 7883967

Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis.

H W Murray1, J S Cervia, J Hariprashad, A P Taylor, M Y Stoeckle, H Hockman.   

Abstract

GM-CSF induces three effects potentially beneficial in visceral leishmaniasis: blood monocyte mobilization, macrophage activation, and amelioration of granulocytopenia. To determine the experimental role and effect of GM-CSF in this intracellular infection, livers from Leishmania donovani-infected BALB/c mice were tested for GM-CSF mRNA expression and mice were treated with anti-GM-CSF antiserum or GM-CSF. L. donovani infection upregulated hepatic GM-CSF mRNA expression by 10-fold, and anti-GM-CSF treatment exacerbated visceral infection and tripled liver parasite burdens 4 wk after challenge. In euthymic mice with established infection, treatment with 1-5 micrograms/d murine GM-CSF induced three dose-related effects: peripheral blood leukocytosis, preferential accumulation of myelomonocytic cells at visceral foci of infection, and leishmanicidal activity comparable to that achieved by IFN-gamma. These effects were either largely or entirely T cell dependent. Treatment with human GM-CSF also induced anti-leishmanial activity but with little effect on peripheral leukocyte number or tissue myelomonocytic cell influx; human G-CSF stimulated marked peripheral granulocytosis and neutrophil tissue accumulation but induced little antileishmanial effect. These results identify a role for endogenous GM-CSF in the initial host defense response to L. donovani, reemphasize the influxing monocyte as an effector cell, and indicate that GM-CSF can be used as an antileishmanial treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883967      PMCID: PMC441456          DOI: 10.1172/JCI117767

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Granulocyte-macrophage and macrophage colony-stimulating factors activate intramacrophage killing of Leishmania mexicana amazonensis.

Authors:  J L Ho; S G Reed; E A Wick; M Giordano
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

2.  Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans.

Authors:  P D Smith; C L Lamerson; S M Banks; S S Saini; L M Wahl; R A Calderone; S M Wahl
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

3.  Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response.

Authors:  K E Squires; R D Schreiber; M J McElrath; B Y Rubin; S L Anderson; H W Murray
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

4.  Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

5.  Culture of human monocytes with granulocyte-macrophage colony-stimulating factor results in enhancement of IFN-gamma receptors but suppression of IFN-gamma-induced expression of the gene IP-10.

Authors:  D S Finbloom; A C Larner; Y Nakagawa; D L Hoover
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

6.  Role and effect of TNF-alpha in experimental visceral leishmaniasis.

Authors:  M C Tumang; C Keogh; L L Moldawer; D C Helfgott; R Teitelbaum; J Hariprashad; H W Murray
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

7.  Colony-stimulating factors and regulation of macrophage tumoricidal and microbicidal activities.

Authors:  P Ralph; C A Nacy; M S Meltzer; N Williams; I Nakoinz; E J Leonard
Journal:  Cell Immunol       Date:  1983-02-15       Impact factor: 4.868

8.  Application of recombinant granulocyte-macrophage colony-stimulating factor has a detrimental effect in experimental murine leishmaniasis.

Authors:  J Greil; B Bodendorfer; M Röllinghoff; W Solbach
Journal:  Eur J Immunol       Date:  1988-10       Impact factor: 5.532

9.  Leishmania antigens presented by GM-CSF-derived macrophages protect susceptible mice against challenge with Leishmania major.

Authors:  T M Doherty; R L Coffman
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

10.  Leishmanicidal mechanisms of human polymorphonuclear phagocytes.

Authors:  K P Chang
Journal:  Am J Trop Med Hyg       Date:  1981-03       Impact factor: 2.345

View more
  30 in total

1.  Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.

Authors:  H W Murray
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 2.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

4.  A candidate vaccine for human visceral leishmaniasis based on a specific T cell epitope-containing chimeric protein protects mice against Leishmania infantum infection.

Authors:  Daniela P Lage; Patrícia A F Ribeiro; Daniel S Dias; Débora V C Mendonça; Fernanda F Ramos; Lívia M Carvalho; Daysiane de Oliveira; Bethina T Steiner; Vívian T Martins; Luísa Perin; Amanda S Machado; Thaís T O Santos; Grasiele S V Tavares; João A Oliveira-da-Silva; Jamil S Oliveira; Bruno M Roatt; Ricardo A Machado-de-Ávila; Antônio L Teixeira; Maria V Humbert; Eduardo A F Coelho; Myron Christodoulides
Journal:  NPJ Vaccines       Date:  2020-08-13       Impact factor: 7.344

5.  Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

Authors:  Henry W Murray; Christina M Lu; Smita Mauze; Sherry Freeman; Andre L Moreira; Gilla Kaplan; Robert L Coffman
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

6.  Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria.

Authors:  J Riopel; M Tam; K Mohan; M W Marino; M M Stevenson
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

7.  An 8-hydroxyquinoline-containing polymeric micelle system is effective for the treatment of murine tegumentary leishmaniasis.

Authors:  Letícia Martins Dos Reis Lage; José Mário Barichello; Daniela Pagliara Lage; Débora Vasconcelos Costa Mendonça; Ana Maria Ravena Severino Carvalho; Marcella Rezende Rodrigues; Daniel Menezes-Souza; Bruno Mendes Roatt; Ricardo José Alves; Carlos Alberto Pereira Tavares; Eduardo Antonio Ferraz Coelho; Mariana Costa Duarte
Journal:  Parasitol Res       Date:  2016-07-01       Impact factor: 2.289

8.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection.

Authors:  H W Murray; J Hariprashad; D F McDermott; M Y Stoeckle
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

10.  Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model.

Authors:  J-H Lee; M-S Roh; Y-K Lee; M-K Kim; J-Y Han; B-H Park; P Trown; D H Kirn; T-H Hwang
Journal:  Cancer Gene Ther       Date:  2009-07-24       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.